FIELD: medicine. SUBSTANCE: retinoid compounds which more predominantly act specifically or selectively upon RARα subtypes than RARα and RARβ ones are of desirable pharmaceutical properties characteristic for retinoids, they are especially introduced for mammalians to treat tumors, for example, acute monocytic leucosis, cervical carcinoma, myeloma, ovarian carcinomas and those at the neck and the head. The suggested method has no undesirable side effects peculiar for retinoids at injection, for example, body weight loss, toxicity for cutaneous- mucous membrane, erythema and terratogenicity. EFFECT: higher efficiency of therapy. 26 cl, 8 dwg, 5 tbl
Authors
Dates
2002-10-20—Published
1996-12-16—Filed